[go: up one dir, main page]

TN2009000357A1 - ACID ADDITION SALTS, HYDRATES AND POLYMORPHS OF 5¬(2,4-DIHYDROXY-5- ISOPROPYL-PHENYL)- 4- (4-MORPHOLIN -4¬YLMETHYL-PHENYL) - ISOXAZOLE-3-CARBOXYLlC ACID ETHYLAMIDE AND FORMULATIONS COMPRISING THESE FORMS - Google Patents

ACID ADDITION SALTS, HYDRATES AND POLYMORPHS OF 5¬(2,4-DIHYDROXY-5- ISOPROPYL-PHENYL)- 4- (4-MORPHOLIN -4¬YLMETHYL-PHENYL) - ISOXAZOLE-3-CARBOXYLlC ACID ETHYLAMIDE AND FORMULATIONS COMPRISING THESE FORMS

Info

Publication number
TN2009000357A1
TN2009000357A1 TNP2009000357A TN2009000357A TN2009000357A1 TN 2009000357 A1 TN2009000357 A1 TN 2009000357A1 TN P2009000357 A TNP2009000357 A TN P2009000357A TN 2009000357 A TN2009000357 A TN 2009000357A TN 2009000357 A1 TN2009000357 A1 TN 2009000357A1
Authority
TN
Tunisia
Prior art keywords
phenyl
polymorphs
morpholin
isoxazole
ylmethyl
Prior art date
Application number
TNP2009000357A
Other languages
English (en)
Inventor
Martin James Drysdale
Brian William Dymock
Christoph Krell
Michael Mutz
Holger Petersen
Weijia Zheng
Original Assignee
Novartis Ag
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38134307&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000357(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Vernalis R&D Ltd filed Critical Novartis Ag
Publication of TN2009000357A1 publication Critical patent/TN2009000357A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TNP2009000357A 2007-03-01 2009-08-28 ACID ADDITION SALTS, HYDRATES AND POLYMORPHS OF 5¬(2,4-DIHYDROXY-5- ISOPROPYL-PHENYL)- 4- (4-MORPHOLIN -4¬YLMETHYL-PHENYL) - ISOXAZOLE-3-CARBOXYLlC ACID ETHYLAMIDE AND FORMULATIONS COMPRISING THESE FORMS TN2009000357A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07103346 2007-03-01
PCT/EP2008/052443 WO2008104595A1 (fr) 2007-03-01 2008-02-28 Sels d'addition acides, hydrates et polymorphes d'éthylamide d'acide 5-(2,4-dihydroxy-5-isopropyl-phényl)-4-(4-morpholin-4-ylméthyl-phényl)-isoxazole-3-carboxylique et préparations comprenant ces formes

Publications (1)

Publication Number Publication Date
TN2009000357A1 true TN2009000357A1 (en) 2010-12-31

Family

ID=38134307

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000357A TN2009000357A1 (en) 2007-03-01 2009-08-28 ACID ADDITION SALTS, HYDRATES AND POLYMORPHS OF 5¬(2,4-DIHYDROXY-5- ISOPROPYL-PHENYL)- 4- (4-MORPHOLIN -4¬YLMETHYL-PHENYL) - ISOXAZOLE-3-CARBOXYLlC ACID ETHYLAMIDE AND FORMULATIONS COMPRISING THESE FORMS

Country Status (40)

Country Link
US (3) US8163747B2 (fr)
EP (2) EP2545921A3 (fr)
JP (1) JP2010520176A (fr)
KR (1) KR20090122218A (fr)
CN (2) CN101636162A (fr)
AR (1) AR065519A1 (fr)
AT (1) ATE552836T1 (fr)
AU (1) AU2008220800B2 (fr)
BR (1) BRPI0807992A2 (fr)
CA (1) CA2678043A1 (fr)
CL (1) CL2008000618A1 (fr)
CO (1) CO6210828A2 (fr)
CR (1) CR10989A (fr)
CY (1) CY1113805T1 (fr)
DK (1) DK2131845T3 (fr)
DO (1) DOP2009000209A (fr)
EA (1) EA017075B1 (fr)
EC (1) ECSP099602A (fr)
ES (1) ES2384906T3 (fr)
GE (1) GEP20115309B (fr)
GT (1) GT200900236A (fr)
HR (1) HRP20120535T1 (fr)
IL (1) IL200401A0 (fr)
MA (1) MA31204B1 (fr)
MX (1) MX2009009233A (fr)
NI (1) NI200900161A (fr)
NZ (1) NZ578854A (fr)
PA (1) PA8771101A1 (fr)
PE (1) PE20090166A1 (fr)
PL (1) PL2131845T3 (fr)
PT (1) PT2131845E (fr)
RS (1) RS52351B (fr)
SI (1) SI2131845T1 (fr)
SM (1) SMAP200900080A (fr)
TN (1) TN2009000357A1 (fr)
TW (1) TW200844102A (fr)
UA (1) UA101950C2 (fr)
UY (1) UY30943A1 (fr)
WO (1) WO2008104595A1 (fr)
ZA (1) ZA200905417B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200922595A (en) * 2007-10-12 2009-06-01 Novartis Ag Organic compounds
TWI450898B (zh) * 2008-07-04 2014-09-01 Sigma Tau Res Switzerland Sa 具有抗腫瘤活性之芳基異唑化合物
EP2370437B1 (fr) * 2008-11-25 2013-09-04 Nerviano Medical Sciences S.r.l. Dérivés bicycliques de pyrazole et d'isoxazole en tant qu'agents antitumoraux et antineurodégénératifs
RU2571566C2 (ru) * 2010-01-21 2015-12-20 Апреа Аб Способ и композиция
US20120309750A1 (en) * 2010-02-17 2012-12-06 Ildong Pharm Co., Ltd. 5-membered heterocycle derivatives and manufacturing process thereof
KR20120031854A (ko) 2010-09-27 2012-04-04 한국전자통신연구원 시간 및 주파수 특징을 이용하는 음악 음원 분리 장치 및 방법
WO2013015661A2 (fr) * 2011-07-28 2013-01-31 Ildong Pharm Co.,Ltd. Nouveaux promédicaments de 5-(2,4-dihydroxy-5-isopropylphényl)-n-éthyl-4-(5-méthyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide
FR3039401B1 (fr) * 2015-07-31 2018-07-13 Les Laboratoires Servier Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004210779B2 (en) 2003-02-11 2010-06-10 Cancer Research Technology Ltd Isoxazole compounds as inhibitors of heat shock proteins
US20060070405A1 (en) * 2004-10-06 2006-04-06 Anheuser-Busch, Inc. Method for the production of amber glass with reduced sulfur-containing emissions
EP2491923A3 (fr) 2007-02-15 2012-12-26 Novartis AG Combinaisons d'agents thérapeutiques pour traiter le cancer
WO2010069458A1 (fr) 2008-12-17 2010-06-24 Merck Patent Gmbh Complexes d'hexahalochromate (iii)

Also Published As

Publication number Publication date
CY1113805T1 (el) 2016-07-27
CN101636162A (zh) 2010-01-27
SI2131845T1 (sl) 2013-02-28
JP2010520176A (ja) 2010-06-10
WO2008104595A1 (fr) 2008-09-04
ZA200905417B (en) 2010-05-26
EP2131845B1 (fr) 2012-04-11
UA101950C2 (ru) 2013-05-27
GEP20115309B (en) 2011-10-25
CL2008000618A1 (es) 2008-09-12
CN102302500A (zh) 2012-01-04
MX2009009233A (es) 2010-06-02
ECSP099602A (es) 2009-12-28
BRPI0807992A2 (pt) 2014-06-17
AR065519A1 (es) 2009-06-10
PE20090166A1 (es) 2009-03-14
AU2008220800B2 (en) 2012-02-16
US20120172592A1 (en) 2012-07-05
ES2384906T3 (es) 2012-07-13
EP2131845A1 (fr) 2009-12-16
TW200844102A (en) 2008-11-16
UY30943A1 (es) 2008-10-31
KR20090122218A (ko) 2009-11-26
IL200401A0 (en) 2010-04-29
GT200900236A (es) 2011-09-14
ATE552836T1 (de) 2012-04-15
US20130296556A1 (en) 2013-11-07
PT2131845E (pt) 2012-07-10
US8487095B2 (en) 2013-07-16
NI200900161A (es) 2010-07-27
AU2008220800A1 (en) 2008-09-04
CO6210828A2 (es) 2010-10-20
HK1139073A1 (en) 2010-09-10
EA017075B1 (ru) 2012-09-28
SMAP200900080A (it) 2010-01-19
EP2545921A2 (fr) 2013-01-16
PL2131845T3 (pl) 2012-09-28
US8163747B2 (en) 2012-04-24
DOP2009000209A (es) 2009-09-15
DK2131845T3 (da) 2012-07-16
EP2545921A3 (fr) 2013-04-10
EA200901141A1 (ru) 2010-04-30
US20100093732A1 (en) 2010-04-15
MA31204B1 (fr) 2010-02-01
HRP20120535T1 (hr) 2012-07-31
RS52351B (sr) 2012-12-31
CR10989A (es) 2010-03-01
CA2678043A1 (fr) 2008-09-04
PA8771101A1 (es) 2009-02-09
NZ578854A (en) 2012-03-30

Similar Documents

Publication Publication Date Title
TN2009000357A1 (en) ACID ADDITION SALTS, HYDRATES AND POLYMORPHS OF 5¬(2,4-DIHYDROXY-5- ISOPROPYL-PHENYL)- 4- (4-MORPHOLIN -4¬YLMETHYL-PHENYL) - ISOXAZOLE-3-CARBOXYLlC ACID ETHYLAMIDE AND FORMULATIONS COMPRISING THESE FORMS
EA201101308A1 (ru) Применение ралфинамида для лечения биполярного расстройства
NO20085068L (no) Fenylamino-benzoksazolsubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
NO20085064L (no) 4,5-difenyl-pyrimidinyl-oksy eller -merkaptosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
MX2014002113A (es) Iminotiazinas sustituidas en 2-espiro y sus mono y bioxidos como inhibidores de enzima de disociacion de proteina precursora amiloide del sitio beta, composiciones, y su uso.
MX383551B (es) Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida
IL210577A (en) Compound 1,2,3,4-tetrahydrocyclopenta [b] indole-3-yl acetic acid, salt, hydrate and solvent, pharmaceutical, compound, salt, hydrate, solvent or pharmaceutical for use as a medicine or treatment Salt, hydrate, solvent or pharmaceutical preparation in the manufacture of a drug and process for the preparation
AR081427A1 (es) Metodo para preparar anticuerpos con propiedades mejoradas
MX2011012122A (es) Derivados de tiofeno.
IL183415A0 (en) Tartrate salt of isofagomine and methods of use
NO20076695L (no) Nye MCHR1-antagonister og deres anvendelse for behandling av MCHR1-medierte tilstander og forstyrrelser
NZ592543A (en) 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
NZ582284A (en) Carbamoyl-cyclohexanes for treating acute mania
JP2010520176A5 (fr)
UA88481C2 (ru) Донепезила фумарат, пригодный для получения фармацевтических композиций
MX2009002906A (es) Derivados de piridina para el tratamiento de trastornos metabolicos relacionados con la resistencia a insulina o hiperglicemia.
MY183153A (en) Crystalline forms of 1-(3-tert-butyl-1-p-tolyl-1h-pyrazol-5-yl) -3-(5-fluoro-2-(1-(2-hydroxyethyl)-indazol-5-yloxy)benzyl) urea hydrochloride
PH12019501566A1 (en) Amide compounds and use thereof
MX2009000762A (es) 4-arilalcoximetil-4-fenil piperidinas y su uso como antagonistas del receptor de neuroquinina para el tratamiento de trastornos del sistema nervioso central.
MY160005A (en) 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
NZ593282A (en) Ethanamine compounds and their use for treating depression
NZ590041A (en) Method of treating anxious major depressive disorder
CU20090151A7 (es) Sales de adición de ácido, hidratos y polimorfos de la etil-amida del ácido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden estas formas
UA98311C2 (ru) Соединение 2-алкилиндазола для лечения определенных расстройств, связанных с цнс, способ его получения (варианты) и фармацевтическая композиция на его основе
MXPA05013717A (es) Derivados de acido 2-etoxi-2-fenilpropionico para el tratamiento de trastornos de lipido.